Skip to main content
logo
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.160
-0.010 (-0.46%)
Aug 26, 2026, 9:31 AM EDT - Market open

Allogene Therapeutics Revenue

Allogene Therapeutics had revenue of $4.64M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $4.64M.

Revenue (ttm)
$4.64M
Revenue Growth
n/a
P/S Ratio
161.58
Revenue / Employee
$30,526
Employees
152
Market Cap
746.26M

Revenue Chart

Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025---
Dec 31, 202422.00K-73.00K-76.84%
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Phathom Pharmaceuticals239.66M
REGENXBIO174.48M
Zevra Therapeutics136.07M
Gyre Therapeutics109.82M
Assembly Biosciences74.85M
CytomX Therapeutics18.30M
Crescent Biopharma11.88M
Shattuck Labs1.00M
Revenue Rankings

ALLO News

More News